Hiroyuki Okada

Hiroyuki Okada

Auto-generated profile, based on publicly available information

Hiroyuki Okada

Himeji Red Cross Hospital, Himeji 670-8540, Japan

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
DUDaisuke Uchida
Daisuke Uchida
ATAkinobu Takaki
Akinobu Takaki
AOAtsushi Oyama
Atsushi Oyama
TATakuya Adachi
Takuya Adachi
NWNozomu Wada
Nozomu Wada
HOHiroyuki Okada
Hiroyuki Okada
Chronic viral hepatitis B and C and non-alcoholic fatty liver disease (NAFLD) have been widely acknowledged to be the leading causes of liver cirrhosis and hepatocellular carcinoma. As anti-viral treatment progresses, the impact of NAFLD is increasing. NAFLD can coexist with chronic viral hepatitis and exacerbate its progression. Oxidative stress has been recognized as a chronic liver disease progression-related and cancer-initiating stress response. However, there are still many unresolved issues concerning oxidative stress, such as the correlation between the natural history of the disease and promising treatment protocols. Recent findings indicate that oxidative stress is also an anti-cancer response that is necessary to kill cancer cells. Oxidative stress might therefore be a cancer-initiating response that should be down regulated in the pre-cancerous stage in patients with risk factors for cancer, while it is an anti-cancer cell response that should not be down regulated in the post-cancerous stage, especially in patients using anti-cancer agents. Antioxidant nutrients should be administered carefully according to the patients’ disease status. In this review, we will highlight these paradoxical effects of oxidative stress in chronic liver diseases, pre- and post-carcinogenesis.

18 January 2018 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
SMSho Mizukawa
Sho Mizukawa
KTKoichiro Tsutsumi
Koichiro Tsutsumi
HKHironari Kato
Hironari Kato
SMShinichiro Muro
Shinichiro Muro
YAYutaka Akimoto
Yutaka Akimoto
HOHiroyuki Okada
Hiroyuki Okada
Endoscopic retrograde cholangiography using a short double-balloon endoscope (DB-ERC) is a promising minimally-invasive method for accessing hepaticojejunostomy (HJ) anastomosis in patients with surgically altered anatomy. We aimed to evaluate the immediate and long-term outcomes of balloon dilatation for benign HJ anastomotic stricture (HJAS) in patients who had previously undergone Whipple’s procedure using a DB-ERC. We conducted a retrospective analysis of 46 patients who underwent balloon dilatation alone with a DB-ERC for benign HJAS between November 2008 and November 2014. The median follow-up duration was 3.5 (interquartile range [IQR], 1.9–5.1) years. The technical and clinical success rates were 100%, and adverse events occurred in 7% (3/46, cholangitis). The median hospitalization period was seven (IQR, 5–10) days. Of 42 patients (91%) followed-up for > 1 year, 24 (51%) had recurrent HJAS at a median of 1.2 (IQR, 0.6–2.9) years after balloon dilatation. The cumulative anastomotic patency rates at 1, 2, and 3 years were 73, 55, and 49%, respectively. In univariate analysis, early stricture formation (< 1 year) was a risk factor for recurrent stenosis, although no statistically significant risk factors were observed in multivariate analysis. Endoscopic balloon dilatation with DB-ERC for benign HJAS is effective and safe, having good immediate technical success and few adverse events. Further improvements to this procedure are needed to prevent recurrent HJAS.

1 September 2021 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
MYMasato Yoshioka
Masato Yoshioka
YSYuichi Sakaguchi
Yuichi Sakaguchi
DUDaisuke Utsunomiya
Daisuke Utsunomiya
SSShinichiro Sonoda
Shinichiro Sonoda
TTTakeichi Tatsuta
Takeichi Tatsuta
HOHiroyuki Okada
Hiroyuki Okada
Polyp size is an important risk factor for colorectal cancer. Many guidelines or reports of colonoscopy make recommendations or provide decision trees according to the size of the detected polyp/adenoma. For example, the recommendation of the colonoscopy surveillance interval after polypectomy is divided based on whether the adenoma size is ≥10  mm or less in some guidelines.1 – 3 According to the preservation and incorporation of valuable endoscopic innovations in real-time endoscopic assessments of the histology of diminutive colorectal polyps proposed by the American Society of Gastrointestinal Endoscopy,4 diminutive lesions smaller than 5 mm should be targeted for resection and discarded because they are associated with low rates of invasive cancer and advanced histology such as villous adenomas and highly atypical adenomas. Regarding the treatment policy for colorectal lesions, polyps of sizes ≤20  mm are assessed to determine whether they can be resected at once with a snare, and the treatment method is selected (either endoscopic mucosal resection or endoscopic submucosal dissection).5

2 December 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EYEriko Yasutomi
Eriko Yasutomi
SHSakiko Hiraoka
Sakiko Hiraoka
SYShumpei Yamamoto
Shumpei Yamamoto
SOShohei Oka
Shohei Oka
MHMami Hirai
Mami Hirai
HOHiroyuki Okada
Hiroyuki Okada
Background and aim: Oral mesalazine and sulfasalazine (SASP) are key drugs for treating ulcerative colitis (UC). The efficacy of switching from one of the several mesalazine formulations to another is largely unknown. This study assessed the efficacy of switching among three types of mesalazine formulation and SASP for UC therapy. Methods: UC patients receiving high-dose mesalazine/SASP who switched to other formulations due to disease activity were considered eligible. Efficacy was evaluated 2, 6, and 12 months after switching. Results: A total of 106 switches in 88 UC patients were analyzed. The efficacy at 2 months after switching was observed in 23/39 (59%) cases from any mesalazine formulation to SASP, in 18/55 (33%) cases from one mesalazine to another, and in 2/12 (17%) cases from SASP to any mesalazine formulation. Nine of 43 effective cases showed inefficacy or became intolerant post-switching. Delayed efficacy more than two months after switching was observed in four cases. Steroid-free remission was achieved in 42/106 (39%) cases—within 100 days in 35 of these cases (83%). Conclusions: Switching from mesalazine to SASP was effective in more than half of cases. The efficacy of switching between mesalazine formulations was lower but may be worth attempting in clinical practice from a safety perspective.

28 March 2023 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MIMasaya Iwamuro
Masaya Iwamuro
TTTakehiro Tanaka
Takehiro Tanaka
HOHiroyuki Okada
Hiroyuki Okada
Review of lymphoma in the duodenum: An update of diagnosis and management

1 January 2012 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MIMasaya Iwamuro
Masaya Iwamuro
HOHiroyuki Okada
Hiroyuki Okada
KTKatsuyoshi Takata
Katsuyoshi Takata
KSKatsuji Shinagawa
Katsuji Shinagawa
SFShigeatsu Fujiki
Shigeatsu Fujiki
KYKazuhide Yamamoto
Kazuhide Yamamoto
To investigate the capacity for 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) to evaluate patients with gastrointestinal lesions of follicular lymphoma. This retrospective case series consisted of 41 patients with follicular lymphoma and gastrointestinal involvement who underwent 18F-FDG-PET and endoscopic evaluations at ten different institutions between November 1996 and October 2011. Data for endoscopic, radiological, and biological examinations performed were retrospectively reviewed from clinical records. A semi-quantitative analysis of 18F-FDG uptake was performed for each involved area by calculating the maximum standardized uptake value (SUVmax). Based on the positivity of 18F-FDG uptake in the gastrointestinal lesions analyzed, patients were subdivided into two groups. To identify potential predictive factors for 18F-FDG positivity, these two groups were compared with respect to gender, age at diagnosis of lymphoma, histopathological grade, pattern of follicular dendritic cells, mitotic rate, clinical stage, soluble interleukin-2 receptor levels detected by 18F-FDG-PET, lactate dehydrogenase (LDH) levels, hemoglobin levels, bone marrow involvement, detectability of gastrointestinal lesions by computed tomography (CT) scanning, and follicular lymphoma international prognostic index (FLIPI) risk. Involvement of follicular lymphoma in the stomach, duodenum, jejunum, ileum, cecum, colon, and rectum was identified in 1, 34, 6, 3, 2, 3, and 6 patients, respectively. No patient had esophageal involvement. In total, 19/41 (46.3%) patients exhibited true-positive 18F-FDG uptake in the lesions present in their gastrointestinal tract. In contrast, false-negative 18F-FDG uptake was detected in 24 patients (58.5%), while false-positive 18F-FDG uptake was detected in 5 patients (12.2%). In the former case, 2/19 patients had both 18F-FDG-positive lesions and 18F-FDG-negative lesions in the gastrointestinal tract. In patients with 18F-FDG avidity, the SUVmax value of the involved gastrointestinal tract ranged from 2.6 to 17.4 (median: 4.7). For the 18F-FDG-negative (n = 22) and -positive (n = 19) groups, there were no differences in the male to female ratios (10/12 vs 4/15, P = 0.186), patient age (63.6 ± 2.4 years vs 60.1 ± 2.6 years, P = 0.323), presence of histopathological grade 1 vs 2 (20/2 and 17/2, P = 1.000), follicular dendritic cell pattern (duodenal/nodal: 13/5 vs 10/3, P = 1.000), mitotic rate (low/partly high, 14/1 vs 10/3, P = 0.311), clinical stage according to the Ann Arbor system (stages IE and IIE/other, 15/7 vs 15/4, P = 0.499), clinical stage according to the Lugano system (stages I and II-1/other, 14/8 vs 14/5, P = 0.489), soluble interleukin-2 receptor levels (495 ± 78 vs 402 ± 83, P = 0.884), LDH levels (188 ± 7 vs 183 ± 8, P = 0.749), hemoglobin levels (13.5 ± 0.3 vs 12.8 ± 0.4, P = 0.197), bone marrow involvement (positive/negative, 1/8 vs 1/10, P = 1.000), detectability by CT scanning (positive/negative, 1/16 vs 4/13, P = 0.335), and FLIPI risk (low risk/other, 16/6 vs 13/6, P = 0.763), respectively in each case. These findings indicate that it is not feasible to predict 18F-FDG-avidity. Therefore, 18F-FDG-PET scans represent a complementary modality for the detection of gastrointestinal involvements in follicular lymphoma patients, and surveillance of the entire gastrointestinal tract by endoscopic examinations is required.